<DOC>
	<DOCNO>NCT00885105</DOCNO>
	<brief_summary>The study compare 2 Groups respect antibody response inactivate influenza vaccine . Observational Objectives : - To describe percentage participant protective Hemagglutinin ( HAI ) antibody titer 3 vaccine antigen study group follow vaccination . - To describe HAI geometric mean titer ( GMTs ) 3 vaccine antigen study group follow vaccination . - To describe safety 2005-2006 pediatric formulation Fluzone® vaccine study group .</brief_summary>
	<brief_title>Evaluation Responses Fluzone® Infants ≥ 6 Months Age Who Did Did Not Receive Fluzone® 2 Months Age</brief_title>
	<detailed_description>This descriptive study provide preliminary comparative information safety immunogenicity Fluzone® vaccine among child give Fluzone® vaccine 2 month age ( Study GRC27 NCT00858468 ) never receive influenza vaccine .</detailed_description>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Participant 6 10 month age day inclusion ( reach 6month reach 11month anniversary birth ) . Available duration study . Born full term pregnancy ( ≥ 36 week ) birth weight ≥ 2.5 kg Parent/legal acceptable representative willing able provide inform consent . Parent/legal acceptable representative able attend schedule visit comply trial procedure . Parent/legal acceptable representative willing permit venipuncture purpose collect blood sample . Previously enrol 2monthold group Study GRC27 approve sponsor enrollment control . Reported allergy egg protein , chicken protein , constituent Fluzone vacccine . Previous history influenza vaccination ( Group 2 subject ) . Receipt vaccine 14 day prior enrollment . An acute illness without fever ( rectal temperature ≥ 38.0 °C [ ≥100.4 °F ] ) 72 hour precede enrollment trial . Known bleed disorder . Participation interventional ( e.g. , vaccine , drug ) clinical trial ( except Study GRC27 ) within 30 day prior enrollment , plan participation another interventional clinical trial prior termination subject 's participation study . Known suspect impairment immunologic function receipt immunosuppressive therapy immunoglobulin since birth . Personal immediate family history congenital immune deficiency . Developmental delay , neurologic disorder , seizure disorder . Chronic medical , congenital developmental disorder could interfere trial conduct completion . Known human immunodeficiency virus ( HIV ) positive hepatitis B surface antigen ( HBsAg ) positive mother . Known HIV , hepatitis B , hepatitis C infection . Receipt blood bloodderived product within past 2 month . Prior history GuillainBarré syndrome . Any condition , opinion investigator , would pose health risk subject interfere evaluation vaccine .</criteria>
	<gender>All</gender>
	<minimum_age>6 Months</minimum_age>
	<maximum_age>11 Months</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>Fluzone® vaccine</keyword>
	<keyword>Influenza</keyword>
</DOC>